Pfizer Ltd (PFIZER)

Healthcare · Pharmaceuticals · NSE · Updated 17 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹4,013.25 ↓ 22.88% (1Y)

🎯 Key Takeaways

Pfizer Ltd is transitioning from a mature pharmaceutical player into a phase of strategic evolution marked by leadership change and capital return focus. The company maintains strong profitability and low leverage, but faces near-term headwinds from CFO succession uncertainty.
Revenue grew 3.8% QoQ to ₹653 in Q1FY27.
⚠️ Leadership vacuum in CFO role with no successor named, potentially disrupting financial governance and investor confidence.

Market Cap

₹18,360

P/E Ratio

25.0

P/B Ratio

4.37

ROE

17.5%

ROCE

23.8%

Debt/Equity

0.00

Promoter

63.9%

✨ Ask AI About PFIZER 📊 Interactive Charts

📖 The Story

Pfizer Ltd is transitioning from a mature pharmaceutical player into a phase of strategic evolution marked by leadership change and capital return focus. The company maintains strong profitability and low leverage, but faces near-term headwinds from CFO succession uncertainty. While quarterly performance remains robust, the absence of a named successor to the CFO and limited growth visibility in its core portfolio suggest a consolidation phase rather than expansion.

📰 What's Happening

The company approved unaudited Q1 FY2026 results showing a 2% sequential rise in net profit to ₹203.93 crores and 11% revenue growth to ₹698.01 crores, driven by operational efficiency. However, the resignation of Executive Director and CFO Amit Agarwal effective October 8, 2026, introduces leadership risk, with no successor announced yet. The board confirmed no material misstatements in the financials following a limited review by BS R & Co. LLP. Additionally, Pfizer declared a final dividend of ₹75 per share (750% of face value) for FY2025-26, payable after August 4, 2026, with AGM scheduled for July 28, 2026, featuring e-voting and remote participation mechanisms compliant with SEBI and MCA norms.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	642	645	629	653
Operating Profit	216	214	221	233
OPM %	33.6%	33.2%	35.1%	35.7%
Net Profit	189	142	200	204
EPS	₹41.32	₹31.01	₹43.68	₹44.69

Quarterly revenue has stabilized around ₹640–653 crores with consistent operating margins near 35%, supporting net profit growth from ₹142 crores (Dec 2025) to ₹204 crores (Jun 2026). EPS rose to ₹44.69 in Q1 FY2026 from ₹31.01 in Dec 2025, reflecting improved profitability. Despite this, total income growth has slowed in recent quarters, indicating limited top-line expansion. The company continues to operate with high operating leverage, but margin gains are incremental rather than structural, suggesting maturity in its current business model rather than aggressive growth.

🔮 Management Outlook & What's Next

Management has not provided forward-looking guidance on revenue, margins, or capital allocation beyond the dividend policy and dividend declaration for FY2025-26. The board emphasized compliance with Ind AS and SEBI norms in financial reporting, and the AGM will focus on procedural formalities rather than strategic updates. No new product launches, pipeline updates, or expansion plans were disclosed in recent filings, implying limited near-term catalysts. The company is prioritizing shareholder returns through dividends while navigating internal leadership transitions.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	46	46	46	46
Reserves	3,705	4,172	3,803	4,157
Borrowings	37	108	43	3
Total Liabilities	4,459	4,911	4,606	4,922
Fixed Assets	132	172	155	678
Investments	0	0	0	0
Total Assets	4,459	4,911	4,606	4,922

The balance sheet remains extremely conservative, with total debt of just ₹3–43 crores against equity of ₹46 crores and reserves of ₹4,157 crores as of March 2026. This results in a near-zero debt-to-equity ratio and minimal net debt, indicating a strong liquidity position. However, the lack of meaningful reinvestment or acquisition activity suggests capital is being returned to shareholders rather than deployed for growth. Total assets have remained stable around ₹4,600–4,900 crores, reflecting a static asset base with no major capex or M&A disclosed.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2026
Operating	+968
Investing	-562
Financing	-798
Net Cash Flow	-392

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	63.9%	63.9%	63.9%	63.9%
FII	2.6%	2.7%	2.8%	1.6%
DII	17.1%	17.0%	16.9%	17.8%
Public	12.1%	11.9%	11.9%	12.0%
# Shareholders	1,03,480	1,00,933	99,545	1,02,478

Promoter holding remains stable at 63.92% over the last four quarters, indicating no dilution or stake sale. Institutional investor interest is growing, with FII shareholding rising from 2.6% in Q2FY26 to 2.81% in Q1FY27, while DII increased from 16.89% to 17.8%. The number of shareholders has slightly declined, but retail participation remains broad at over 100,000 holders. No pledging activity is evident, and the rise in institutional ownership may reflect confidence in dividend yield and stability amid sector headwinds.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.45 L Cr	36.8	18.7%	14.6%	0.05
DIVISLAB	2.44 L Cr	83.5	23.0%	17.4%	0.00
TORNTPHARM	1.83 L Cr	76.9	15.1%	25.7%	1.76
ZYDUSLIFE	1.10 L Cr	24.6	16.8%	16.6%	0.43
CIPLA	1.10 L Cr	32.6	13.2%	9.8%	0.01
LAURUSLABS	1.03 L Cr	94.1	20.8%	20.6%	0.45
DRREDDY	95,591	29.6	10.1%	8.4%	0.17
AUROPHARMA	94,420	25.6	12.8%	9.8%	0.20
LUPIN	93,605	16.5	27.9%	24.7%	0.26
MANKIND	92,842	45.4	13.9%	12.7%	0.38

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Leadership vacuum in CFO role with no successor named, potentially disrupting financial governance and investor confidence. 2. Absence of growth catalysts — flat revenue trends and no new product or market expansion updates despite strong profitability. 3. High dividend payout (750% of face value) may strain cash flows if profitability softens, especially with net loss of ₹392 crores in latest quarter due to financing and investing outflows. 4. Sector-specific regulatory and pricing pressures in pharmaceuticals remain unaddressed in disclosures, posing long-term headwind risk.

📋 Recent Filings

🧠 Analyst's Read

Pfizer Ltd is a cash-generative, low-debt pharmaceutical entity returning capital aggressively through dividends, but its near-term outlook is clouded by CFO succession uncertainty and lack of growth initiatives. Investors should monitor the appointment of a new CFO and any strategic updates at the upcoming AGM for clarity on future capital allocation. While financial fundamentals remain sound, the absence of a clear growth narrative warrants caution, particularly in a sector facing patent cliffs and pricing scrutiny.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on PFIZER

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when PFIZER files new disclosures

Track PFIZER filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track PFIZER — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd